1. Home
  2. PRM vs NAMS Comparison

PRM vs NAMS Comparison

Compare PRM & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Perimeter Solutions SA

PRM

Perimeter Solutions SA

HOLD

Current Price

$35.49

Market Cap

4.9B

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$33.00

Market Cap

4.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRM
NAMS
Founded
2018
2019
Country
United States
Netherlands
Employees
371
100
Industry
Newspapers/Magazines
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9B
4.1B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PRM
NAMS
Price
$35.49
$33.00
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
8
Target Price
$27.50
$46.75
AVG Volume (30 Days)
1.3M
1.1M
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$30.45
$17.96
Revenue Next Year
$8.44
$540.65
P/E Ratio
$51.56
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.79
$17.97
52 Week High
$38.17
$42.21

Technical Indicators

Market Signals
Indicator
PRM
NAMS
Relative Strength Index (RSI) 57.07 55.23
Support Level $30.08 $30.34
Resistance Level $38.17 $37.27
Average True Range (ATR) 1.42 1.60
MACD 0.05 0.30
Stochastic Oscillator 67.18 92.58

Price Performance

Historical Comparison
PRM
NAMS

About PRM Perimeter Solutions SA

Perimeter Solutions Inc is a solutions provider for the Fire Safety and Specialty Products industries. The company's products and operations are managed and reported in two operating segments. Its Fire Safety segment provides fire retardants and firefighting foams, as well as specialized equipment and services typically offered in conjunction with the company's retardant and foam products. The Specialty Products segment develops, produces, and markets phosphorus pentasulfide (P2S5)-based products used in lubricant additives, as well as in pesticide, mining chemical, and battery applications.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Share on Social Networks: